An observational study in Substance-Related Disorders, sponsored by BC Centre on Substance Use. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by BC Centre on Substance Use · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Substance-Related Disorders with a site in Canada — 26 open to participants now, 29 under way, none of them phase 3. Substance-Related Disorders · Canada.
Among the 81 studies in Substance-Related Disorders with a site in Canada, this one is one of 9 that started in 2023, is one of 9 observational ones, reaches primary completion later than 25 of the 28 other live ones, and was the 70th registered.
2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.
Browse Substance-Related Disorders studies →26 of the 81 studies in Substance-Related Disorders with a site in Canada are open now. Recruiting first, the newest first:
St. Joseph's Healthcare Hamilton · Sites in Canada
Ages 18–55
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–70
University Health Network, Toronto · Sites in Canada
Ages 18–85 · Healthy volunteers
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18–55
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 250 across 299 observational studies indexed under Substance-Related Disorders.
Median enrollment 74 across the 71 interventional studies, 520 across the 9 observational. Of the 47 that completed or were terminated, 4 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 81 have an industry lead sponsor. The 10 most frequent:
BC Centre on Substance Use is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
BC Centre on Substance Use has 1 study filed under Substance-Related Disorders — fewer than ten, so there is no comparison to draw.
9 of the studies in Substance-Related Disorders with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04812613Ottawa Hospital Research InstituteTobacco-Concurrent Addictions in At-Risk Youth in Ottawa | 2026-12-31 |
| NCT05704582Ciusss de L'Est de l'Île de MontréalRCT Comparing Avatar Intervention to Supportive Intervention to Reduce Cannabis Use in Patients With Psychotic Disorders | 2027-01 |
| NCT07146633Centre for Addiction and Mental HealthEfficacy of an EMDR App for PTSD and SUD | 2027-01-30 |
| NCT03249428Ottawa Hospital Research InstituteCytisine vs Nicotine Replacement Therapy | 2027-03 |
| NCT06856161Fraser HealthA Novel Blood Test as a Biomarker in Mental Health | 2027-03-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 81 studies in Substance-Related Disorders with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Despite substance use causing significant harms and cost to our health care system, British Columbia's (BC) current addiction treatment system remains under-resourced and fragmented. To address this, Providence Health Care (PHC) is expanding clinical addiction services as part of the Road to Recovery Initiative (R2R). The proposed study aims to generate novel data to promote fully evidence-informed and coordinated substance use care in BC and beyond. This study will explore substance use treatment trajectories, identify challenges and areas for growth in addiction health services, characterize important features of patients accessing care, and improve our provincial capacity to promptly tailor approaches to care in response to the substance use crisis.
Since the declaration of a public health emergencies in Canada in 2016 and the United States in 2017 in response to rising overdose deaths, more than 400,000 Americans and 38,000 Canadians have died from drug overdoses. Within Canada, British Columbia (BC) shoulders a substantial burden of that loss, exceeding 13,000 overdose deaths since 2016. BC's unpredictable and toxic drug supply combined with the province's siloed and fragmented addiction treatment system are key contributors. The burden of disease, however, is not restricted to criminalized substances. The prevalence of alcohol misuse across Canada is at an unprecedented high, between 2015 - 2016 over 77,000 hospitalizations were attributed to alcohol related harms, with the highest rates again being observed in BC. Further, the substance use crisis has had a disproportional impact on Indigenous peoples as a consequence of colonialism and systemic racism. Accordingly, the provincial government and representative health organizations have urgently called for the development and implementation of a coordinated system of culturally safe substance use care that spans a continuum, ranging from harm reduction services to abstinence-based programming.
To address care gaps, Providence Health Care (PHC)-a regional health authority in the province of BC - in collaboration with the provincial government's Ministry of Mental Health and Addictions (MMHA), Vancouver Coastal Health (VCH) (another regional health authority) - is spearheading the Road to Recovery (R2R) Initiative, a first-of-its-kind model of substance use care. BC's existing substance use treatment system is comprised of both publicly- and privately-funded service providers in bed-based and outpatient settings. Quality and standards vary substantially between service providers, and inter-organizational communication is extremely limited. The R2R model of care seeks to address this by: (1) improving access to care through the creation of approximately 100 new substance use treatment beds; and (2) offering comprehensive substance use management along the entire care continuum (i.e., harm reduction, withdrawal management, bed-based recovery and outpatient longitudinal follow-up). A focus of the R2R model is inclusivity and honouring what matters most to individual patients to foster a safe recovery environment. Thus, close collaborations with Providence Health Care's Indigenous Wellness and Reconciliation (IWR) team and the BC Centre on Substance Use Indigenous Initiatives team has supported the integration of Indigenous cultural safety into the R2R model including through workflows and daily programming thereby meeting patients where they are at when they want and are in need of substance use care.
The proposed study will constitute a cohort of patients accessing substance use treatment services parallel to the phased operationalization of R2R in the VCH region. In this mixed-methods prospective cohort design, patients receiving R2R services will be observed through primary data collection at baseline and 12-month follow up via (1) interviewer-administered surveys and (2) semi-structured qualitative interviews over a 5-year study period. Participants will be asked to provide consent for the use of personal identifiers (i.e., a unique and persistent identifier issued to all provincial residents to access healthcare) to support secondary data-collection through (1) 30-day prospective follow-up from time of R2R admission using electronic medical record chart review, and (2) linkage annually to provincial health and administrative databases over a five-year follow-up period. A purposive sample of cohort participants will also be invited to participate in baseline and 12-month follow-up qualitative interviews.
Employing a convergent parallel design, quantitative and qualitative data collection will occur in parallel, of which results are later compared and related to one another. This will be an iterative process, as findings from each convergent analysis will inform adaptations and additions to data collection processes across implementation phases of R2R. The data will be leveraged to promote evidence-informed and coordinated substance use care through the integration of population and administrative data From cohort participant questionnaires, the investigators will gain an understanding of substance use treatment trajectories, identify challenges and areas for growth in addiction health services, characterize important features of patients accessing care, and improve our provincial capacity to promptly tailor approaches to care in response to the substance use crisis. Engaging with Indigenous participants for each study outcome will be critical to understanding the impact of building Indigenous cultural safety into the R2R model on relevant outcomes, and is supported by the IWR. Lastly, this work will support surveillance of evolving substance use trends, identify fixed and modifiable risk factors impacting substance use trajectories, as well build local, regional, and provincial partnerships to promptly respond to health challenges associated with the dynamic landscape of the substance use crisis. Collaboration with IWR throughout this work ensures that the collection and use of Indigenous data respects and upholds the principles of Indigenous data governance.
People who have accessed or been admitted to any R2R service.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals with a substance use disorder who access or are admitted to an R2R service
Other: Specialized clinical service access
A new model of addiction care that will offer comprehensive and coordinated service delivery
Substance use patterns following R2R access
Metrics include frequency of use in the 12-months following R2R access
Time frame: 1 year
Health care utilization patterns following R2R access
Metrics include the count of hospitalizations, readmissions, and emergency department visits.
Time frame: 1 year
Substance use treatment trajectories
Metrics include completion status of substance use treatment programs within 12 months after R2R access.
Time frame: 1 year
Health among study participants over time
Metrics include count of comorbidities in the 12 months following R2R access.
Time frame: 1 year
Plan to share: Undecided
Started Oct 2023 (actual). Primary completion is estimated for Oct 2028, 60 months after the start.
Of 123 non-industry observational studies under Substance-Related Disorders, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 60. This study's planned 60 months is above that.
Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 18 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
BC Centre on Substance Use